secwatch.observer — SEC 8-K summary
======================================

Issuer:     HCW Biologics Inc. (HCWB)
CIK:        0001828673
Form:       8-K
Filed at:   2025-03-28T23:59:59+00:00
Accession:  0000950170-25-046716
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HCW Biologics reports FY2024 net loss $30M; going concern doubt, plans financing
--------------------------------------------------------------------------------

- FY2024 revenue $2.6M (vs $2.8M); net loss $30.0M (vs $25.0M); legal expenses $15.9M from arbitration.
- Q4 2024 revenue $394,804 (vs $1.3M); net loss $3.4M (vs $10.7M).
- Substantial doubt about going concern; financing plan includes $20M equity line with Square Gate and $7M milestone from WY Biotech license.
- Nasdaq extension to April 28 (bid price) and June 15 (other rules); special meeting March 31 for reverse split and conversions.
- IND cleared for HCW9302 Phase 1 in alopecia areata; Phase 2 ovarian cancer study closed due to poor enrollment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828673/000095017025046716/0000950170-25-046716-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828673/000095017025046716/hcwb-20250328.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-046716

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer